VTE prevalence, by SCT status
| . | Full cohort . | European . | Latine . | African . | East Asian . | South Asian . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Noncarriers . | SCT carriers . | Noncarriers . | SCT carriers . | Noncarriers . | SCT carriers . | Noncarriers . | SCT carriers . | Noncarriers . | SCT carriers . | Noncarriers . | SCT carriers . | |
| VTE, n (%) | 93 833 (2.25%) | ≥490 (2.57%) | 82 411 (2.59%) | 34 (4.28%) | 7162 (1.21%) | 67 (1.68%) | 3616 (1.92%) | 389 (2.74%) | 433 (0.27%) | <5∗ | 211 (0.51%) | <5 |
| PE, n (%) | 37 552 (0.90%) | ≥301 (1.58%) | 32 808 (1.03%) | 22 (2.77%) | 2789 (0.47%) | 44 (1.10%) | 1717 (0.91%) | 235 (1.65%) | 160 (0.10%) | <5 | 78 (0.19%) | <5 |
| Isolated DVT, n (%) | 56 281 (1.36%) | ≥189 (1.01%) | 49 603 (1.58%) | 12 (1.55%) | 4373 (0.74%) | 23 (0.58%) | 1899 (1.02%) | 154 (1.10%) | 273 (0.17%) | <5 | 133 (0.32%) | <5 |
| . | Full cohort . | European . | Latine . | African . | East Asian . | South Asian . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Noncarriers . | SCT carriers . | Noncarriers . | SCT carriers . | Noncarriers . | SCT carriers . | Noncarriers . | SCT carriers . | Noncarriers . | SCT carriers . | Noncarriers . | SCT carriers . | |
| VTE, n (%) | 93 833 (2.25%) | ≥490 (2.57%) | 82 411 (2.59%) | 34 (4.28%) | 7162 (1.21%) | 67 (1.68%) | 3616 (1.92%) | 389 (2.74%) | 433 (0.27%) | <5∗ | 211 (0.51%) | <5 |
| PE, n (%) | 37 552 (0.90%) | ≥301 (1.58%) | 32 808 (1.03%) | 22 (2.77%) | 2789 (0.47%) | 44 (1.10%) | 1717 (0.91%) | 235 (1.65%) | 160 (0.10%) | <5 | 78 (0.19%) | <5 |
| Isolated DVT, n (%) | 56 281 (1.36%) | ≥189 (1.01%) | 49 603 (1.58%) | 12 (1.55%) | 4373 (0.74%) | 23 (0.58%) | 1899 (1.02%) | 154 (1.10%) | 273 (0.17%) | <5 | 133 (0.32%) | <5 |
Note that, to respect 23andMe research participant privacy, we are unable to provide specific counts in which n was <5.